Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clin... ( SAN DIEGO Aug. 21 /- Ardea Biosci...)

Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial

Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 1 study evaluating RDEA594 in normal healthy volunteers. RDEA594 is the Company's lead product candidate for the treatment of gout.

"Regulatory clearance for us to proceed with our Phase 1 study of RDEA594, within six months from designation as a clinical candidate is a testament to the efficiency of our development organization, and the importance we place on our gout program -- a program we intend to expand with second-generation compounds from our exciting ongoing research in this area," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "Earlier this quarter, we initiated a Phase 2a proof-of-concept study of RDEA806, a prodrug of RDEA594, which should allow us to provide an early confirmation of RDEA594's activity in the target population of patients with gout."

This Phase 1, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult male volunteers.

About Gout

An estimated 3-5 million people in the United States, and approximately 5 million people in the European Union, suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

Post Your Comments:

(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...

(Date:5/22/2013)... REHOVOT, Israel , May 22, 2013 ... a leading developer and provider of microRNA-based molecular diagnostics, ... President and Chief Executive Officer of Rosetta Genomics, will ... Conference taking place from June 3-6, 2013 in New ... Tuesday, June 4 th at 2:00 p.m. Eastern ...

(Date:5/22/2013)... FRANKLIN LAKES, N.J. , May 22, 2013 /PRNewswire/ ... ), a leading global medical technology company, announced today ... This is BD,s fifth Sustainability Report and it continues ... sustainability. "We believe the principles of ... communities and addressing healthcare challenges of societies — are ...

Breaking Medicine Technology:Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3 BD Issues 2012 Sustainability Report 2 BD Issues 2012 Sustainability Report 3

[0] Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives [0] Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference [0] BD Issues 2012 Sustainability Report

... efficacy and benefits of early treatment ... with liraglutide versus glimepiride, SAN FRANCISCO, ... of the American Diabetes Association (ADA),demonstrated that once-daily liraglutide when ... in,patients with type 2 diabetes, as compared to glimepiride, a ...

... Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, Inc.,(Nasdaq: ... and,commercializing novel pain management therapies, announced today the,publication ... candidate, NGX-4010, in the,journal Neurology. The paper, titled, ... Painful HIV,Neuropathy," will appear in the June 10, ...

Cached Medicine Technology:Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 2 Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 3 Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes 4 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

(Date:5/22/2013)... 2013 Zensah® Compression Apparel released a ... titled "Breast pain while running affects one-third ... could help." According to the article, a British study ... amount suffer from breast pain while running but do ... issue. , Zensah emphasizes the importance for women ...

(Date:5/22/2013)... 2013 Successful Therapy for Parents ... Psychotherapy in the Silver Lake community of Los ... as progression to existing Parents and Couples counseling ... parenting therapy has always been suggested, but now ... now specializes in all aspects of relationships ...

(Date:5/22/2013)... Twenty student-led startup companies at Arizona State ... intensive startup accelerator designed to help them execute their ... local jobs as part of ASU’s Edson Student ... offers approximately 20 student teams up to $20,000 each ... launch their for-profit, more-than-profit or nonprofit ventures. The program, ...

(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Migraines ... suffering, but new research indicates the combination of the ... a smaller brain. , , Already aware that people ... wanted to determine if having both conditions together affected ... 2 percent -- isn,t alarming, study authors said, but ...

(Date:5/22/2013)... May 22, 2013 Hurricane preparation isn’t ... home. That’s why Amica Insurance is reminding ... the upcoming hurricane season. , “An important part of ... Cook, a senior assistant vice president at Amica Insurance. ... before the threat of a storm.” , Flood damage ...

[0] Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Reviewing Insurance Policies: a Key Part of Hurricane Preparations

... LAS VEGAS, Jan. 8 (LVCC S227) ... a new initiative to make,radio more accessible to ... people around the world., At a press ... Vegas,the three organizations announced the global accessible radio ...

... Slumping Economy &, Presidential Election May Mean for Private Equity in ... ... With credit markets in,turmoil, the economy in a seeming slowdown and ... Equity Analyst Outlook,Conference on January 29-30 at the Grand Hyatt in New ...

... most common indication worldwide for pediatric transplantation, biliary atresia ... disease in newborns. Recently, Childrens Hospital of Pittsburgh of ... with biliary atresia face that lead to the need ... children undergoing their first liver transplant are diagnosed with ...

... population growth since the beginning of the XXth Century, ... slave trade and colonization. The regions population in fact ... in 2005. The latest United Nations projections, published in ... billion inhabitants being reached between the present and 2050., ...

... and improves ... customer ... subsidiary of Hays plc., one of the world,s leading specialist,recruitment ... processes and improve customer service., Hays stated that it ...

... MONTVALE, N.J., Jan. 8 Jennifer J. Day, Senior ... announces the,addition of Kenneth A. Sylvia as publisher of ... the healthcare industry who brings to DHM,30 years of ... client bases we serve," Day said. DHM is a ...

Cached Medicine News:Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 2 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 3 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 4 Health News:NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired 5 Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2 Health News:Children's Hospital physicians publish review of transplant issues in patients with biliary atresia 2 Health News:Sub-Saharan Africa: the population emergency 2 Health News:Sub-Saharan Africa: the population emergency 3 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 2 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 3 Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 4

NPR, Harris Corporation and Towson University Launch Global Effort To Make Radio Accessible to Hearing and Sight Impaired Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference Children's Hospital physicians publish review of transplant issues in patients with biliary atresia Sub-Saharan Africa: the population emergency Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing Kenneth A. Sylvia Named as New Publisher of Current Psychiatry

... is suspected, every minute counts. ... allows rapid determination of the ... a single whole blood sample. ... within minutes - saving you ...

... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...

... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...

A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....

Medicine Products:

TROPT Sensitive NUVO Surgical Light - Double Light Head Monitor Ready NUVO Surgical Light - Single Light Head Anti-Myelin Associated Glycoproteins (MAG) Western Blot